Prostate Cancer

Changes in Patient-Reported Outcomes Linked to Better Survival in Metastatic Prostate Cancer

Charles Bankhead

September 2016, Vol 7, No 8 - Prostate Cancer

Patient-reported outcomes had significant associations with survival in metastatic castration-resistant prostate cancer (mCRPC), suggesting potential implications for clinical management, reported Tomasz M. Beer, MD, Oregon Health & Science University, Knight Cancer Institute, Portland, and colleagues, at the 2016 International Society for Pharmacoeconomics and Outcomes Research annual meeting. [ Read More ]

Shorter Hypofractionated Therapy New Standard for Prostate Cancer

Phoebe Starr

August 2016, Vol 7, No7, Special Issue: Payers’ Perspectives in Oncology - Prostate Cancer

Men with intermediate-risk prostate cancer can safely undergo radiation administered in larger fractions for 4 weeks (moderate hypofractionation) as an alternative to conventional radiation administered for 8 weeks, according to the results of a randomized, controlled, noninferiority clinical trial presented at ASCO 2016.

[ Read More ]

Is the Glass Half Empty or Half Full? First Study Compares Robotic-Assisted Surgery and Open Radical Prostatectomy

Alice Goodman

August 2016, Vol 7, No7, Special Issue: Payers’ Perspectives in Oncology - Prostate Cancer

The first randomized trial to compare robotic-assisted prostatectomy with conventional open radical prostatectomy found no meaningful differences between these techniques in urinary and sexual function or in the rate of positive surgical margins in men with localized prostate cancer in the first 12 weeks after surgery (Yaxley JW, et al. Lancet. 2016 Jul 26. Epub ahead of print). The 24-month results will be published at a later time.

[ Read More ]